Abstract
‘Lower is better’ underpins the management of low-density lipoprotein cholesterol (LDL-C) in the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) dyslipidaemia guidelines [1]. Recent trials in very high-risk patients with ezetimibe and PCSK9 monoclonal antibody therapy provide robust support, showing incremental reduction in cardiovascular events at lower LDL-C levels [2-4], with no evidence to suggest a threshold for clinical benefit from LDL-C lowering [5]. The available data also do not indicate safety issues associated with very low LDL-C levels attained with these efficacious therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
